Daniel Egle

5.7k total citations · 2 hit papers
88 papers, 2.3k citations indexed

About

Daniel Egle is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Daniel Egle has authored 88 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Oncology, 33 papers in Pulmonary and Respiratory Medicine and 29 papers in Cancer Research. Recurrent topics in Daniel Egle's work include Advanced Breast Cancer Therapies (24 papers), Breast Cancer Treatment Studies (24 papers) and HER2/EGFR in Cancer Research (22 papers). Daniel Egle is often cited by papers focused on Advanced Breast Cancer Therapies (24 papers), Breast Cancer Treatment Studies (24 papers) and HER2/EGFR in Cancer Research (22 papers). Daniel Egle collaborates with scholars based in Austria, Germany and Switzerland. Daniel Egle's co-authors include Christian Marth, Heidi Fiegl, Martin Widschwendter, Ian Jacobs, Joanne Young, Gilbert Spizzo, Daniel J. Weisenberger, Peter W. Laird, Mihaela Campan and Elisabeth Mueller‐Holzner and has published in prestigious journals such as Nature Genetics, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Daniel Egle

83 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Epigenetic stem cell signature in cancer

2006 775 citations Martin Widschwendter, Heidi Fiegl et al. profile →
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

2022 204 citations Luca Gianni, Chiun‐Sheng Huang et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel Egle Austria	18	1.0k	990	613	397	211	88	2.3k
Christian Schem Germany	24	913 0.9×	790 0.8×	839 1.4×	402 1.0×	167 0.8×	124	2.2k
Nilsa C. Ramirez United States	20	899 0.9×	802 0.8×	615 1.0×	200 0.5×	469 2.2×	45	2.4k
Gro Wiedswang Norway	20	1.1k 1.1×	374 0.4×	763 1.2×	338 0.9×	82 0.4×	38	1.7k
Fan Jin United States	23	1.2k 1.2×	657 0.7×	334 0.5×	518 1.3×	122 0.6×	75	2.2k
Veli‐Matti Kosma Finland	19	711 0.7×	675 0.7×	283 0.5×	280 0.7×	115 0.5×	49	1.9k
Marta A. Crispens United States	25	498 0.5×	568 0.6×	296 0.5×	185 0.5×	163 0.8×	62	1.8k
Marcella Baldewijns Belgium	20	301 0.3×	858 0.9×	389 0.6×	622 1.6×	88 0.4×	62	1.6k
Kyle C. Strickland United States	20	957 1.0×	485 0.5×	343 0.6×	225 0.6×	264 1.3×	72	2.2k
Fabian Trillsch Germany	25	577 0.6×	802 0.8×	568 0.9×	187 0.5×	132 0.6×	128	2.1k
Véronique D’Hondt France	21	781 0.8×	298 0.3×	241 0.4×	335 0.8×	88 0.4×	83	1.3k

Countries citing papers authored by Daniel Egle

Since Specialization

Citations

This map shows the geographic impact of Daniel Egle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Egle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Egle more than expected).

Fields of papers citing papers by Daniel Egle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Egle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Egle. The network helps show where Daniel Egle may publish in the future.

Co-authorship network of co-authors of Daniel Egle

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Egle. A scholar is included among the top collaborators of Daniel Egle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Egle. Daniel Egle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Singer, C, Daniel Egle, Leopold Oehler, et al.. (2025). 356P Real-world (RW) outcomes with first-line (1L) ribociclib (RIB)+endocrine therapy (ET) in patients (pts) with HR+, HER2– metastatic breast cancer (MBC): Final analysis of the phase IV REACH AUT study. ESMO Open. 10. 104927–104927.

Wimmer, Kerstin, Dominik Hlauschek, Marija Balić, et al.. (2024). Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?. Breast Cancer Research and Treatment. 205(2). 227–239. 1 indexed citations

Lackner, Michaela, Débora C. Coraça‐Huber, Klaus Faserl, et al.. (2024). Surface Topography, Microbial Adhesion, and Immune Responses in Silicone Mammary Implant-Associated Capsular Fibrosis. International Journal of Molecular Sciences. 25(6). 3163–3163. 3 indexed citations

Egle, Daniel, et al.. (2024). Shear-Wave Elastography Gradient Analysis of Newly Diagnosed Breast Tumours: A Critical Analysis. Diagnostics. 14(15). 1657–1657. 1 indexed citations

Guarneri, Valentina, François P. Duhoux, Daniel Egle, et al.. (2024). Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer. Future Oncology. 20(18). 1237–1250. 1 indexed citations

Bartsch, Rupert, Anna S. Berghoff, Julia Furtner, et al.. (2024). 187P Stage I results of a phase II study of datopotamab deruxtecan (DATO-DXd) in triple-negative breast cancer (TNBC) patients (pts) with active brain metastases (TUXEDO-2). ESMO Open. 9. 103209–103209. 4 indexed citations

Gianni, Luca, Chiun‐Sheng Huang, Daniel Egle, et al.. (2023). LBA19 Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study. Annals of Oncology. 34. S1258–S1259. 10 indexed citations

Gruber, Leonhard, et al.. (2023). Peritumoural Strain Elastography of Newly Diagnosed Breast Tumours: Does Maximum Peritumoural Halo Depth Correlate with Tumour Differentiation and Grade?. Diagnostics. 13(12). 2064–2064. 2 indexed citations

Daniaux, Martin, Leonhard Gruber, Tobias De Zordo, et al.. (2023). Preoperative staging by multimodal imaging in newly diagnosed breast cancer: Diagnostic performance of contrast-enhanced spectral mammography compared to conventional mammography, ultrasound, and MRI. European Journal of Radiology. 163. 110838–110838. 13 indexed citations

10.

Faserl, Klaus, et al.. (2023). Quantitative Proteomic Characterization of Foreign Body Response towards Silicone Breast Implants Identifies Chronological Disease-Relevant Biomarker Dynamics. Biomolecules. 13(2). 305–305. 12 indexed citations

11.

Morandi, Evi M., et al.. (2023). Long-Term Results after Autologous Breast Reconstruction with DIEP versus PAP Flaps Based on Quality of Life and Aesthetic Outcome Analysis. Journal of Clinical Medicine. 12(3). 737–737. 8 indexed citations

12.

Egle, Daniel, et al.. (2023). Is It All about Surface Topography? An Intra-Individual Clinical Outcome Analysis of Two Different Implant Surfaces in Breast Reconstruction. Journal of Clinical Medicine. 12(4). 1315–1315. 10 indexed citations

13.

Egle, Daniel, Verena Wieser, Afschin Soleiman, et al.. (2023). The Tomosynthesis Broken Halo Sign: Diagnostic Utility for the Classification of Newly Diagnosed Breast Tumors. Tomography. 9(6). 1987–1998.

14.

Gianni, Luca, Chiun‐Sheng Huang, Daniel Egle, et al.. (2022). Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Annals of Oncology. 33(5). 534–543. 204 indexed citations breakdown →

15.

Bartsch, Rupert, Simon Peter Gampenrieder, Gabriel Rinnerthaler, et al.. (2022). Updated Austrian treatment algorithm in HER2+ metastatic breast cancer. Wiener klinische Wochenschrift. 134(1-2). 63–72. 2 indexed citations

16.

Filipits, Martin, Margaretha Rudas, Christian F. Singer, et al.. (2021). The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor–Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8. Clinical Cancer Research. 27(21). 5931–5938. 1 indexed citations

17.

Bianchini, Giampaolo, Matteo Dugo, Chiun‐Sheng Huang, et al.. (2021). LBA12 Predictive value of gene-expression profiles (GEPs) and their dynamics during therapy in the NeoTRIPaPDL1 trial. Annals of Oncology. 32. S1283–S1284. 15 indexed citations

18.

Steger, Guenther G., Daniel Egle, Rupert Bartsch, et al.. (2020). Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2− advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT. The Breast. 50. 64–70. 13 indexed citations

19.

Singer, Christian F., Yen Y. Tan, Florian Fitzal, et al.. (2017). Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer. Clinical Cancer Research. 23(14). 3676–3683. 32 indexed citations

20.

Berger, Regina, Heidi Fiegl, Hans H. Goebel, et al.. (2010). Toll‐like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. Cancer Science. 101(4). 1059–1066. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact